Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BIOS BioPlus Acquisition (BIOS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About BioPlus Acquisition Stock (NASDAQ:BIOS) 30 days 90 days 365 days Advanced Chart Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get BioPlus Acquisition alerts:Sign Up Key Stats Today's Range$10.79▼$10.8050-Day Range$10.75▼$10.8452-Week Range$10.05▼$11.68Volume5,600 shsAverage Volume122,781 shsMarket Capitalization$209.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBioPlus Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. BioPlus Acquisition Corp. was incorporated in 2021 and is based in New York, New York.Read More… Receive BIOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioPlus Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOS Stock News HeadlinesUpstream Bio Pursues $100 Million IPO Plan With Encouraging Trial ResultsSeptember 25, 2024 | seekingalpha.comPayMate Plans to Acquire DigiAsia BiosSeptember 24, 2024 | marketwatch.comWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.December 22, 2024 | Behind the Markets (Ad)Gigabyte details BIOS roll-out plan to neutralize Sinkclose vulnerability — eligible AMD CPUs should be patched by end of the monthAugust 24, 2024 | yahoo.comMadison's Mirus Bio to be acquired by MilliporeSigma for $600 millionMay 28, 2024 | bizjournals.comBiogen enters deal to acquire HI-Bio for $1.8bnMay 23, 2024 | msn.comBiogen’s Strategic Acquisition of HI-Bio and Diversification into Orphan Drug Market Prompt ‘Buy’ RatingMay 22, 2024 | markets.businessinsider.comBiogen to buy San Francisco startup developing a drug for kidney disease for $1.2BMay 22, 2024 | bizjournals.comSee More Headlines BIOS Stock Analysis - Frequently Asked Questions When did BioPlus Acquisition IPO? BioPlus Acquisition (BIOS) raised $180 million in an initial public offering (IPO) on Friday, December 3rd 2021. The company issued 18,000,000 shares at a price of $10.00 per share. Cantor served as the underwriter for the IPO. What other stocks do shareholders of BioPlus Acquisition own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioPlus Acquisition investors own include TransMedics Group (TMDX), Deciphera Pharmaceuticals (DCPH) and BioMarin Pharmaceutical (BMRN). Company Calendar Today12/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorUnclassified Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:BIOS CUSIPN/A CIK1856653 Webbioplusspac.com Phone212-287-4092FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares19,370,000Free Float14,990,000Market Cap$209.20 million OptionableNot Optionable Beta0.01 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:BIOS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPlus Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPlus Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.